Efficacy of a paclitaxel-eluting biliary metal stent with sodium caprate in malignant biliary obstruction: a prospective randomized comparative study

Abstract

Backgrounds The placement of a self-expandable metal stent (SEMS) is widely used in patients with unresectable malignant biliary obstructions, but SEMSs are susceptible to occlusion by tumor ingrowth or overgrowth. The efficacy and safety of a novel paclitaxel-eluting biliary metal stent incorporating sodium caprate (MSCPM-III) were compared prospectively with those of a covered metal stent (CMS) in patients with malignant biliary obstructions.

Methods Patients with unresectable distal malignant biliary obstructions (n = 106) were prospectively enrolled in this study at multiple treatment centers. Stents were placed endoscopically: MSCPM-III in 54 patients and CMS in 51 patients. The patients received systemic chemotherapy regimens according to their disease characteristics.

Results The two groups did not differ significantly in basic characteristics or mean follow-up period. Stent occlusion occurred in 14 patients who received MSCPM-III and in 11 patients who received CMS. Time to recurrent biliary obstruction (RBO) and survival time did not differ significantly between the two groups (P  = 0.84 and P = 0.29, respectively). However, tumor size at 2 months after stent insertion was significantly decreased in patients in the MSCPM-III group with bile duct cancers or those who experienced stent migration compared with the CMS group. Complications, including cholangitis and pancreatitis, were found to be acceptable in both groups.

Conclusions Although compared with a CMS the MSCPM-III did not significantly influence time to RBO or survival duration in patients with malignant biliary obstructions, MSCPM-III reduced tumor volume and was used safely in humans.

• References

• 1 Andersen JR, Sorensen SM, Kruse A. et al. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice. Gut 1989; 30: 1132-1135
• 2 Smith AC, Dowsett JF, Russell RC. et al. Randomised trial of endoscopic stenting versus surgical bypass in malignant low bileduct obstruction. Lancet 1994; 344: 1655-1660
• 3 Saleem A, Leggett CL, Murad MH. et al. Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc 2011; 74: 321-327
• 4 Almadi MA, Barkun AN, Martel M. No benefit of covered vs uncovered self-expandable metal stents in patients with malignant distal biliary obstruction: a meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 27-37
• 5 Wagner HJ, Knyrim K, Vakil N. et al. Plastic endoprostheses versus metal stents in the palliative treatment of malignant hilar biliary obstruction. A prospective and randomized trial. Endoscopy 1993; 25: 213-218
• 6 Nakai Y, Isayama H, Komatsu Y. et al. Efficacy and safety of the covered Wallstent in patients with distal malignant biliary obstruction. Gastrointest Endosc 2005; 62: 742-748
• 7 Kim HS, Lee DK, Kim HG. et al. Features of malignant biliary obstruction affecting the patency of metallic stents: a multicenter study. Gastrointest Endosc 2002; 55: 359-365
• 8 Hausegger KA, Kleinert R, Lammer J. et al. Malignant biliary obstruction: histologic findings after treatment with self-expandable stents. Radiology 1992; 185: 461-464
• 9 Park do H, Kim MH, Choi JS. et al. Covered versus uncovered wallstent for malignant extrahepatic biliary obstruction: a cohort comparative analysis. Clin Gastroenterol Hepatol 2006; 4: 790-796
• 10 Lee DK, Kim HS, Kim KS. et al. The effect on porcine bile duct of a metallic stent covered with a paclitaxel-incorporated membrane. Gastrointest Endosc 2005; 61: 296-301
• 11 Suk KT, Kim JW, Kim HS. et al. Human application of a metallic stent covered with a paclitaxel-incorporated membrane for malignant biliary obstruction: multicenter pilot study. Gastrointest Endosc 2007; 66: 798-803
• 12 Lee SS, Shin JH, Han JM. et al. Histologic influence of paclitaxel-eluting covered metallic stents in a canine biliary model. Gastrointest Endosc 2009; 69: 1140-1147
• 13 Song TJ, Lee SS, Yun SC. et al. Paclitaxel-eluting covered metal stents versus covered metal stents for distal malignant biliary obstruction: a prospective comparative pilot study. Gastrointest Endosc 2011; 73: 727-733
• 14 Jang SI, Kim JH, Kim M. et al. Porcine feasibility and safety study of a new paclitaxel-eluting biliary stent with a Pluronic-containing membrane. Endoscopy 2012; 44: 825-831
• 15 Jang SI, Kim JH, You JW. et al. Efficacy of a metallic stent covered with a paclitaxel-incorporated membrane versus a covered metal stent for malignant biliary obstruction: a prospective comparative study. Dig Dis Sci 2013; 58: 865-871
• 16 Jang SI, Lee SJ, Jeong S. et al. Efficacy of a multiplex paclitaxel emission stent using a pluronic® mixture membrane versus a covered metal stent in malignant biliary obstruction: a prospective randomized comparative study. Gut Liver 2017; 11: 567-573
• 17 Jeong D, Lee DH, Lee DK. et al. Nonvascular drug-eluting stent coated with sodium caprate-incorporated polyurethane for the efficient penetration of paclitaxel into tumor tissue. J Biomater Appl 2015; 29: 1133-1144
• 18 Fujioka T, Kondou T, Fukuhara A. et al. Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. Hepatol Res 2003; 26: 10-14
• 19 Isayama H, Hamada T, Yasuda I. et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015; 27: 259-264
• 20 Misra SP, Dwivedi M. Reflux of duodenal contents and cholangitis in patients undergoing self-expanding metal stent placement. Gastrointest Endosc 2009; 70: 317-321
• 21 van Berkel AM, van Marle J, Groen AK. et al. Mechanisms of biliary stent clogging: confocal laser scanning and scanning electron microscopy. Endoscopy 2005; 37: 729-734
• 22 Dua KS, Reddy ND, Rao VG. et al. Impact of reducing duodenobiliary reflux on biliary stent patency: an in vitro evaluation and a prospective randomized clinical trial that used a biliary stent with an antireflux valve. Gastrointest Endosc 2007; 65: 819-828
• 23 Bang BW, Jeong S, Lee DH. et al. The biodurability of covering materials for metallic stents in a bile flow phantom. Dig Dis Sci 2012; 57: 1056-1063
• 24 Isayama H, Kawabe T, Nakai Y. et al. Management of distal malignant biliary obstruction with the ComVi stent, a new covered metallic stent. Surg Endosc 2010; 24: 131-137
• 25 Hu B, Wang TT, Wu J. et al. Antireflux stents to reduce the risk of cholangitis in patients with malignant biliary strictures: a randomized trial. Endoscopy 2014; 46: 120-126
• 26 Ghaneh P, Costello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007; 56: 1134-1152
• 27 Kalinowski M, Alfke H, Kleb B. et al. Paclitaxel inhibits proliferation of cell lines responsible for metal stent obstruction: possible topical application in malignant bile duct obstructions. Invest Radiol 2002; 37: 399-404
• 28 Bang S, Jang SI, Lee SY. et al. Molecular mechanism of local drug delivery with paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug. Gastroenterol Res Pract 2015; 2015: 568981